Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > LATEST
LATEST
-
BUSINESS Daiichi Sankyo Assigns COO Okuzawa as CEO from April
February 3, 2025
-
BUSINESS Datroway Now in PIII Study for Adjuvant NSCLC Setting: Daiichi Sankyo
February 3, 2025
-
REGULATORY Lixiana Now Set for Label Expansion; 11 Drugs to Get Orphan Tags
February 3, 2025
-
BUSINESS Daiichi Sankyo to Promote COO Okuzawa to CEO
January 31, 2025
-
BUSINESS Sarepta Drops DMD Drug Patent Claim against Nippon Shinyaku in Japan
January 31, 2025
-
BUSINESS Novo Launches Once-Weekly Insulin Awiqli in Japan
January 31, 2025
-
REGULATORY CSL’s HAE Drug, Tecentriq Sarcoma Use Clear Panel Review; February Approval Expected
January 31, 2025
-
BUSINESS J&J Files Nipocalimab for Generalized Myasthenia Gravis in Japan
January 31, 2025
-
BUSINESS Chugai Logs Record Earnings in 2024 on Upbeat Exports to Roche
January 31, 2025
-
BUSINESS Chugai, SoftBank in AI Deal to Speed Up Drug Development
January 31, 2025
-
BUSINESS Chugai, GSK Join Hands in Anti-Dengue Antibody Development
January 31, 2025
-
BUSINESS Takeda Drops Epilepsy Med Soticlestat after PIII Miss
January 31, 2025
-
BUSINESS Takeda Ups Full-Year Guidance on Slower Vyvanse Generic Erosion
January 31, 2025
-
BUSINESS Julie Kim Tapped to Take Over Helm of Takeda in 2026
January 31, 2025
-
REGULATORY MHLW to Take Balanced Approach in Dealing with Off-Year Revisions: Minister
January 31, 2025
-
BUSINESS Quviviq Off to Good Start in GP Promotion in December: Intage
January 31, 2025
-
BUSINESS Takeda CEO Weber to Retire Next Year, Succeeded by US Head
January 30, 2025
-
BUSINESS Pfizer Japan Resolved to Drive Vaccine Demand, New Drug Launches: President
January 30, 2025
-
REGULATORY MHLW Orders Label Revisions for Lixiana, Keytruda, and More Drugs
January 30, 2025
-
REGULATORY Pfizer’s Litfulo Braced for Price Cut after Cost-Effectiveness Assessment
January 30, 2025
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…